Sanibel Captiva Trust Company Inc. reduced its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 4.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,455 shares of the company’s stock after selling 793 shares during the quarter. Sanibel Captiva Trust Company Inc.’s holdings in AstraZeneca were worth $1,361,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also recently added to or reduced their stakes in the business. Able Wealth Management LLC acquired a new stake in AstraZeneca during the fourth quarter worth about $27,000. Pathway Financial Advisers LLC acquired a new stake in AstraZeneca during the first quarter worth about $29,000. Pin Oak Investment Advisors Inc. increased its stake in AstraZeneca by 468.4% during the fourth quarter. Pin Oak Investment Advisors Inc. now owns 449 shares of the company’s stock worth $30,000 after acquiring an additional 370 shares during the last quarter. RFP Financial Group LLC increased its stake in AstraZeneca by 56.3% during the first quarter. RFP Financial Group LLC now owns 494 shares of the company’s stock worth $33,000 after acquiring an additional 178 shares during the last quarter. Finally, Northwest Financial Advisors acquired a new stake in AstraZeneca during the fourth quarter worth about $34,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.
AstraZeneca Stock Performance
NASDAQ:AZN traded up $0.35 during trading hours on Tuesday, reaching $85.13. 2,484,259 shares of the stock were exchanged, compared to its average volume of 5,335,562. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69. The firm has a 50 day simple moving average of $79.47 and a 200-day simple moving average of $73.56. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $85.65. The stock has a market capitalization of $263.95 billion, a P/E ratio of 41.56, a P/E/G ratio of 1.36 and a beta of 0.45.
AstraZeneca Cuts Dividend
The business also recently declared a Semi-Annual dividend, which will be paid on Monday, September 9th. Stockholders of record on Friday, August 9th will be given a dividend of $0.49 per share. This represents a dividend yield of 1.8%. The ex-dividend date of this dividend is Friday, August 9th. AstraZeneca’s payout ratio is 48.04%.
Analyst Upgrades and Downgrades
Several brokerages have commented on AZN. Citigroup upgraded AstraZeneca to a “strong-buy” rating in a research note on Monday, June 24th. BMO Capital Markets increased their price target on AstraZeneca from $80.00 to $82.00 and gave the company an “outperform” rating in a report on Friday, April 26th. Barclays raised AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. TD Cowen increased their price target on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Finally, Argus increased their price target on AstraZeneca from $80.00 to $85.00 and gave the company a “buy” rating in a report on Thursday, May 30th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, AstraZeneca has a consensus rating of “Buy” and an average target price of $89.75.
Get Our Latest Analysis on AstraZeneca
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
See Also
- Five stocks we like better than AstraZeneca
- Canadian Penny Stocks: Can They Make You Rich?
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Lowe’s Stock: Hold Now, Buy it When it Dips
- How to Invest in Biotech Stocks
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.